Hikma Plans Turkey, Mideast, Africa Acquisitions For Up To $600 Million
This article was originally published in PharmAsia News
Executive Summary
Jordan's Hikma Pharmaceuticals has plans to broaden its global reach beyond Middle East, particularly in Turkey and Egypt and elsewhere in Africa, and has $600 million it could use to acquire other companies, a senior executive said.
You may also be interested in...
US CDC’s Adult RSV Vaccine Recommendations In Flux With Impending FDA Approvals
Moderna touts enriched Phase II/III population and severe RSV data as CDC advisory committee re-evaluates shared clinical decision-making and prepares for expected June votes on Moderna’s mRNA-1345 and expanded adult use of GSK’s Arexvy.
Roche Nabs FDA Approval For First Of Its Kind Malaria Test
The US FDA has approved Roche’s cobas Malaria test, which screens blood donors in the US for malaria. The cobas is the first such diagnostic to win agency approval.
Deal Watch: Gilead Acquires Xilio’s IL-12 Activating Candidate
Plus deals involving Avalo/AlmataBio, AbbVie/Parvus, NovaBay/Eyenovia, Bayer/Aignostics, Merck & Co./Pearl, tech transfer agreements and deals in brief.